新冠病毒|前沿|可减少99%新冠病毒载量!《科学》报道全新抗疫希望( 二 )


“我们的数据表明在感染早期使用masitinib能取得最好的效果,这是抗病毒药物最能起效的时间段,”本研究的另一名负责人Savas Tay教授说道,“因为masitinib能简单口服给药,早期治疗是个可行的策略 。未来我们需要在临床试验中更仔细地研究它的潜在益处 。”
参考资料:
[1] Nir Drayman et al., (2021), Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2, Science, DOI: 10.1126/science.abg5827
[2] AB Science announces the publication of an article in the world-renowned journal Science that confirms potential of masitinib as a treatment of Covid-19 with anti-viral activity against SARS-CoV-2 and all tested variants of concern, Retrieved July 20, 2021, from https://www.globenewswire.com/news-release/2021/07/20/2265951/0/en/AB-Science-announces-the-publication-of-an-article-in-the-world-renowned-journal-Science-that-confirms-potential-of-masitinib-as-a-treatment-of-Covid-19-with-anti-viral-activity-ag.html
新冠病毒专题
癌症突破
智慧之光
热门前沿
【新冠病毒|前沿|可减少99%新冠病毒载量!《科学》报道全新抗疫希望】新冠病毒|前沿|可减少99%新冠病毒载量!《科学》报道全新抗疫希望
文章图片


推荐阅读